Status:

COMPLETED

Functional Usability and Feasibility Testing of the Profound Matrix™ System

Lead Sponsor:

Candela Corporation

Conditions:

Wrinkle

Acne Scars - Mixed Atrophic and Hypertrophic

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

This is a non-randomized, multi-center, open-label clinical trial evaluating the efficacy and clinical feasibility of the Profound Matrix device for electrocoagulation and for treatment of wrinkles an...

Eligibility Criteria

Inclusion

  • Healthy Male or Female
  • Age 18 to 75
  • Subjects seeking treatment for facial, abdominal, or back wrinkles reduction, skin texture improvement and/or acne scars appearance improvement and willing to undergo RF treatments for improvement
  • Presence of at least mild wrinkles or mild acne scars or uneven skin texture, as assessed by the Investigator
  • Willingness to provide signed, informed consent to participate in the study
  • Willingness to allow photography of treated areas, and to release their use for scientific/educational and/or promotional purposes

Exclusion

  • Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding
  • Pacemaker or internal defibrillator or any active electrical implant anywhere in the body
  • Superficial metal or other implants in the treatment area, except superficial dental implants, unless these implants can be removed or covered with rolled gauze during treatment
  • Current skin cancers in the treatment area or history of melanoma
  • History of current cancer and subject has undergone chemotherapy within the last 12 months
  • Severe concurrent conditions, such as cardiac disorders
  • Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications
  • Herpes Simplex Virus (HSV) in the intended treatment area unless treated following a prophylactic regimen
  • Poorly controlled endocrine disorders such as diabetes
  • Active skin condition in the treatment area such as sores, psoriasis, eczema, or rash, open wounds, and severe active inflammatory acne.
  • History of abnormal wound healing, keloid, or hypertrophic scar formation, as well as very dry and fragile skin
  • History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitis disorders
  • Known allergy to lidocaine, tetracaine, Xylocaine, epinephrine or ProNox (nitrous oxide (laughing gas))
  • Patients on systemic corticosteroid therapy in past six months
  • Is taking medication(s) for which sunlight is a contraindication
  • Tattoos or permanent makeup in the intended treatment area
  • Excessively tanned skin
  • Subjects with pigmented lesions that are considered not acceptable by the study investigator or any condition that, in the investigator's opinion, would make it unsafe to treat.
  • Subject has hair and is unwilling to have hair removed from the treatment area
  • Subjects has undergone facelift in the last 12 months
  • Subject has undergone aesthetics treatments/procedures (e.g. facial resurfacing and deep chemical peeling) within the last 4 months) within the intended to treat area
  • Subject has undergone Botox in the treatment area within the last 3 months
  • Subject has non-permanent filler in the last 3 months within the intended to treat area
  • Subject has permanent filler (e.g. silicone) within the intended to treat area
  • Subject has absorbable facial threads within the last 2 years within the intended to treat area
  • Subject has non-absorbable facial threads within the intended to treat area aa. Subject is using a topical in the treatment area that the Investigator's deems the subject unsuitable for the study.
  • bb. In the opinion of the Investigator, the subject is unwilling or unable to adhere to the study requirements

Key Trial Info

Start Date :

October 28 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 29 2023

Estimated Enrollment :

193 Patients enrolled

Trial Details

Trial ID

NCT06192550

Start Date

October 28 2020

End Date

December 29 2023

Last Update

February 13 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Candela Institue for Excellence

Marlborough, Massachusetts, United States, 01752

2

NY Derm

New York, New York, United States, 10028

3

OptiSkin

New York, New York, United States, 10128

4

Laser & Vein Specialists of the Carolinas

Charlotte, North Carolina, United States, 28207

Functional Usability and Feasibility Testing of the Profound Matrix™ System | DecenTrialz